Research and Analysis Journals 6(10): 01-09, 2023 e-ISSN: 2589-9228, p-ISSN: 2589-921x © 2023, RAJ 1 Research and Analysis Journals, Vol. 6, Issue 10, October, 2023 Review Article Novel Carriers and Approaches Insight in Diabetes Mellitus Rohit Sarna, Somesh Saxena, Sudeep Bhardwaj, Ashutosh Aggarwal Seth G.L. Bihani S.D. College of Technical Education, SriGanganagar, Rajasthan Abstract: Diabetes mellitus is one of the the most common, oldest and non communicable chronic disease in India.Diabetes is a serious, costly and heterogeneous metabolic disorder which ischaracterized by chronically elevated blood glucose levels (BGLs) and an inability to maintain BGL homeostasis. According to Indian council of medical research (ICMR, section 1,2005) diabetes is defined as a metabolic cum vascular syndrome of multiple etiologies factorise by hyperglycemia with disturbance of carbohydrate, protein and fat metabolism resulting from insulin deficiency or resistance to insulin or both.According to American diabetes association (ADA) diabetes is is defined as a group of metabolic diseases characterized by inappropriate hyperglycemia resulting from defects in insulin secretion, insulin action or both. Introduction Diabetes is the fourth or fifth leading cause of death in most developed countries with the substantial evidence to be epidemic in many developing and newly industrialized countries, affecting about 25% of the population. The majority of diabetes cases broadly falls in two categories i.e.Type 1 Diabetes and Type 2 diabetes. Type 1 diabetes occurs because the insulin-producing cells of the pancreas (beta cells) are damaged (as shown in fig) Type 2 diabetes is characterized by insulin resistance, or a deficiency in cellular response to insulin in the bloodstream( in fig)Besides these types of diabetes, gestational diabetes has also been reported in pregnant women.Normal blood glucose level is 70 to 100 mg/dL when fasting and upto 140 mg/dL two hours after eating. In diabetes, 100 to 125 mg/dL in prediabetes, more than 140 mg/dL when fasting and more than 200 mg/dL two hours after eating. Treatment of diabetes need constant monitoring of blood glucose level, regulating it through modified dietary sugar intake, physical exercise and insulin therapy (subcutaneous administration) to attain normogly.Therefore the current standard of care for type 1 and advanced type 2 diabetes involves daily subcutaneous insulin injections, and frequent finger pricks to draw blood for the measurement of BGLs.Additionally, periodic measurement of blood glucose may not detect large fluctuations in BGLs which occur between points of measurement. Therefore, systems which improve blood glucose monitoring, or “close the loop” between glucose measurement and insulin delivery, are highly desirable.In order to optimize different routes of insulin therapy, novel drug delivery systems have been suggested, and alternative routes of administration have been investigated. One such method used for the advancement of medicine is nanotechnology. Nanotechnology involves the use of particles within 1–100 nm. It is the size of these particles, as well as their large surface to volume ratio, that has increased interest in their application for molecular therapeutic targeting. The use of nanoparticles (NPs) allows for improved bioavailability, controlled release, and targeted drug delivery (TDD). To date, the advancement of nanomedicine has focused on the safe, effective, and accurate delivery of drugs foran array of pathological conditions. Studies employing biodegradable natural/synthetic polymeric nanoparticles (PNPs) and manipulating the distinctive properties of these nanomaterials for TDD have been undertaken. Advancements in nanoscience for insulin therapeutics have brought about research for the development of insulin nanocarriers, insulin smart-drug delivery systems (stimuli-responsive), insulin pumps, novel insulin analogs, and insulin nanosensors for the effective treatment of DM. This review will be focusing on the alternative route of administration (oral or pulmonary) or reducing the injection doses are beneficial to reduce the inconvenience and drawbacks associated with this conventional method. Problems possed by the antidiabetics Antidiabetics are effortlessly accessible in the internationalmarket Most of the oral hypoglycemics are available either in the form of tablets and capsules.However, these dosage forms offer various untoward effects/limitations like gastric irritation, diarrhea, loss of appetite,lactic acidosis in people with abnormal kidney or liverfunction due to gastrointestinal degradation, insolubility inwater and do not comply with the safety and efficacy of the patients. These adverse effects revealed the limited accessibility of conventional dosage forms at desired site of action, higher systemic toxicity, narrowtherapeutic window, complex dosing schedule for long-termtreatment (Sutradhar & Sumi, 2014). Two major factorsrequired for the drugs to be effective are their optimalconcentration at the desired site of action and persistent effective concentration for a longer period of time. After immediate release, oral hypoglycemics get absorb from thebiological membranes and move toward the site of action.However, to attain the